Free Research Report Download:
The Cancer Market Outlook To 2014
Free Pharmaceutical Market Research Reports
Biotechnology
Corporate & Fiscal
Drug Delivery
Health Products
Hospital Markets
Indication Areas
Medical Devices
Prescription Medicines
R&D
Custom Research
Pharmaceutical Events & Conferences
Contact
Terms & Conditions
Privacy
Home >
The Pharmaceutical Market: Brazil
Management Report
Published: January 2010
Pages: 115
Tables: For full details, please email keithw@cmsinfo.com
From: GBP 595.00 Buy Now!
Research from: Espicom
Sector: Prescription Medicines
Espicom’s in-depth pharmaceutical market reports are ideal for executives wanting to understand the key drivers in pharmaceutical markets and have access to a wealth of statistical data. Each report opens with an outlook section that provides analysis of the market, 5-year market forecasts, national data projections, market outlook and key developments such as regulation, pricing/reimbursement, intellectual property, health facilities and government policy. The report also provides extensive background information, population trends, health status, health expenditure, organisation & administration, hospital services, medical personnel, healthcare development, market access information, trade data for raw materials and finished products and essential industry contacts. Included with the report are 3 free quarterly updated outlook reports, enabling you to keep up to date with market developments for a year.
Espicom's highly regarded world pharmaceutical market reports have been redesigned to provide enhanced strategic intelligence in a user-friendly format. Each report provides in-depth information, setting the pharmaceutical market in context. The reports provide:
Five-year projections for economic, demographic, health expenditure, health workforce and pharmaceutical market indicators.
Specialised intelligence on OTCs, generics, biologics and biosimilars.
Exclusive economic and demographic data from the Economist Intelligence Unit (EIU) for each market in the series.
A separate statistical health file, comprising health expenditure, health infrastructure, health services and health personnel.
The reports are updated quarterly, providing you with the latest information for a full year. In addition, the service will keep you up to date with market and industry news on a regular basis.
BRAZIL - MARKET REVIEW
Brazil is the second most attractive BRIC market for pharmaceutical producers. Controlled drug prices have increased below inflation levels but price controls are not directly linked to consumption levels. In fact, between 1997 and 2008, the pharmaceutical market by volume increased significantly only in 2004. Demand should increase as the country is emerging from the economic downturn much quicker than anticipated, therefore the outlook is positive compared to other Latin American markets. The exchange rate of the real against the US dollar fell in early 2009, but it has now recovered. This is good news for producers as imports are now cheaper; Brazil, contrary to what happens in other BRIC countries such as India, still relies on raw material imports, which diminishes its market strength. Recent regulatory developments include the implementation of the National Drug Control System, published in November 2009; registration requirements for APIs, published in November 2009; and a new labelling & packaging regulation, published in September 2009. ANVISA is also working on a draft for the regulation of biologic copies; the aim is to encourage local production of these medicines.
The pharmacy sector in dollar values registered a slow growth in 2009. Future OTC sales are expected to be affected by the new advertising regulation, enforced in June 2009, and the new dispensing practices, published in August 2009. One of the new dispensing measures was that OTC medicines could no longer be sold over the counter. This, however, was overturned by ABRAFARMA in October 2009. Generics sales continue to grow at a higher rate than the overall pharmacy sector, and they are expected to represent 20% of the sector by volume in 2010. In September 2009, it was rumoured that the local generic producer, Neo Química, was being acquired by Pfizer, but instead it was grabbed by Hypermarcas in December 2009. This was the second major acquisition in the generic sector in 2009, following sanofi-aventis’ acquisition of Medley. This wave of acquisitions is a blow for the government which has been trying to create a leading local pharmaceutical group with the help of the National Bank for Economic & Social Development (BNDES). EMS, Aché and Eurofarma remain local, and a hypothetic merger of Aché and Eurofarma would be supported by the government.
Local manufacturing investments continue in order to increase market positioning locally and internationally. Biolab plans to create a new R&D facility in 2010. Cristália has inaugurated a new R&D centre; the company claims to be the local producer with the highest R&D portfolio and investments. EMS is investing in a new Drug Delivery Systems (DDS) platform. Eurofarma continues to invest in its animal health division in the local market, whilst it has acquired an Argentine pharmaceutical producer in order to develop its international operations. Hipolabor is building a second manufacturing plant for the production of antibiotics. Even public producers follow the same trend. Fundação para o Remédio Popular (FURP), for example, has inaugurated a new manufacturing plant for the production of generic medicines, the first of its type.
Leading foreign pharmaceutical companies are strengthening their operations. Daiichi-Sankyo, the only Japanese company with manufacturing operations in Brazil, is expanding its plant. GlaxoSmithKline has announced a multibillion alliance with Fiocruz’s Bio-Manguihos to develop vaccines. Nycomed has announced investments of US$300.0 million over the next five years. Novartis is setting up a vaccines plant. Brazil is the most important BRIC market for sanofi-aventis. The company has increased its market share following the acquisition of Medley, and has announced its plans to create a plant for the production of generic contraceptives. Solvay has announced the creation of a new share services centre. In the wholesaling sector, Celesio, the largest European wholesaler, has acquired a majority state in the Panpharma group. Other companies are re-assessing their operations. Boehringer Ingelheim, for instance, has signed a third-party manufacturing agreement with Zambon, whilst Roche has announced plans to sell its manufacturing plant in Brazil.
Five-year projections for economic, demographic, health expenditure, health workforce and pharmaceutical market indicators.
Specialised intelligence on OTCs, generics, biologics and biosimilars.
Exclusive economic and demographic data from the Economist Intelligence Unit (EIU) for each market in the series.
A separate statistical health file, comprising health expenditure, health infrastructure, health services and health personnel.
The reports are updated quarterly, providing you with the latest information for a full year. In addition, the service will keep you up to date with market and industry news on a regular basis.
BRAZIL - MARKET REVIEW
Brazil is the second most attractive BRIC market for pharmaceutical producers. Controlled drug prices have increased below inflation levels but price controls are not directly linked to consumption levels. In fact, between 1997 and 2008, the pharmaceutical market by volume increased significantly only in 2004. Demand should increase as the country is emerging from the economic downturn much quicker than anticipated, therefore the outlook is positive compared to other Latin American markets. The exchange rate of the real against the US dollar fell in early 2009, but it has now recovered. This is good news for producers as imports are now cheaper; Brazil, contrary to what happens in other BRIC countries such as India, still relies on raw material imports, which diminishes its market strength. Recent regulatory developments include the implementation of the National Drug Control System, published in November 2009; registration requirements for APIs, published in November 2009; and a new labelling & packaging regulation, published in September 2009. ANVISA is also working on a draft for the regulation of biologic copies; the aim is to encourage local production of these medicines.
The pharmacy sector in dollar values registered a slow growth in 2009. Future OTC sales are expected to be affected by the new advertising regulation, enforced in June 2009, and the new dispensing practices, published in August 2009. One of the new dispensing measures was that OTC medicines could no longer be sold over the counter. This, however, was overturned by ABRAFARMA in October 2009. Generics sales continue to grow at a higher rate than the overall pharmacy sector, and they are expected to represent 20% of the sector by volume in 2010. In September 2009, it was rumoured that the local generic producer, Neo Química, was being acquired by Pfizer, but instead it was grabbed by Hypermarcas in December 2009. This was the second major acquisition in the generic sector in 2009, following sanofi-aventis’ acquisition of Medley. This wave of acquisitions is a blow for the government which has been trying to create a leading local pharmaceutical group with the help of the National Bank for Economic & Social Development (BNDES). EMS, Aché and Eurofarma remain local, and a hypothetic merger of Aché and Eurofarma would be supported by the government.
Local manufacturing investments continue in order to increase market positioning locally and internationally. Biolab plans to create a new R&D facility in 2010. Cristália has inaugurated a new R&D centre; the company claims to be the local producer with the highest R&D portfolio and investments. EMS is investing in a new Drug Delivery Systems (DDS) platform. Eurofarma continues to invest in its animal health division in the local market, whilst it has acquired an Argentine pharmaceutical producer in order to develop its international operations. Hipolabor is building a second manufacturing plant for the production of antibiotics. Even public producers follow the same trend. Fundação para o Remédio Popular (FURP), for example, has inaugurated a new manufacturing plant for the production of generic medicines, the first of its type.
Leading foreign pharmaceutical companies are strengthening their operations. Daiichi-Sankyo, the only Japanese company with manufacturing operations in Brazil, is expanding its plant. GlaxoSmithKline has announced a multibillion alliance with Fiocruz’s Bio-Manguihos to develop vaccines. Nycomed has announced investments of US$300.0 million over the next five years. Novartis is setting up a vaccines plant. Brazil is the most important BRIC market for sanofi-aventis. The company has increased its market share following the acquisition of Medley, and has announced its plans to create a plant for the production of generic contraceptives. Solvay has announced the creation of a new share services centre. In the wholesaling sector, Celesio, the largest European wholesaler, has acquired a majority state in the Panpharma group. Other companies are re-assessing their operations. Boehringer Ingelheim, for instance, has signed a third-party manufacturing agreement with Zambon, whilst Roche has announced plans to sell its manufacturing plant in Brazil.